Aruna Bio is advancing neural exosome therapies for neurodegenerative diseases. Leveraging its proprietary platform and manufacturing, the company aims to develop treatments that cross the blood-brain barrier to promote anti-inflammatory responses and self-repair in conditions lacking effective solutions. Aruna has gained FDA clearance for its first IND, AB126, targeting acute ischemic stroke - a pioneering step for exosome-based therapy in neurology. AB126 also shows promise for chronic conditions like ALS, evidenced by positive data in an SOD1 murine model. The platform's versatility allows integration with other therapeutics, enhancing delivery across the blood-brain barrier directly to disease sites.